Laboratorio de Investigacao em Dermatologia e Imunodeficiencias, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Front Immunol. 2018 Dec 18;9:2993. doi: 10.3389/fimmu.2018.02993. eCollection 2018.
Harnessing dendritic cells (DC) to treat HIV infection is considered a key strategy to improve anti-HIV treatment and promote the discovery of functional or sterilizing cures. Although this strategy represents a promising approach, the results of currently published trials suggest that opportunities to optimize its performance still exist. In addition to the genetic and clinical characteristics of patients, the efficacy of DC-based immunotherapy depends on the quality of the vaccine product, which is composed of precursor-derived DC and an antigen for pulsing. Here, we focus on some factors that can interfere with vaccine production and should thus be considered to improve DC-based immunotherapy for HIV infection.
利用树突状细胞（DC）治疗 HIV 感染被认为是改善抗 HIV 治疗和促进功能性或根治性治疗方法发现的关键策略。尽管该策略具有广阔的应用前景，但是目前已发表的临床试验结果表明，仍有优化其疗效的空间。除了患者的遗传和临床特征外，基于 DC 的免疫疗法的疗效还取决于疫苗产品的质量，该疫苗产品由前体细胞衍生的 DC 和用于冲击的抗原组成。在这里，我们重点关注一些可能会干扰疫苗生产的因素，这些因素应在考虑范围内，以改进基于 DC 的 HIV 感染免疫疗法。
